Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Roche Holding (SWX:ROG) reported highly positive Phase II results for its amylin analogue petrelintide in the ZUPREME-1 trial.
The drug, co-developed with Zealand Pharma, achieved clinically meaningful and sustained weight loss in people living with overweight and obesity.
Petrelintide showed a favorable tolerability profile, including fewer gastrointestinal side effects compared to placebo.
The data support Roche’s plans for late-stage development and potential combination obesity therapies.
For investors watching the growing obesity drug space, this update puts Roche Holding (SWX:ROG) more clearly on the map. The shares most recently traded at CHF341.2, with a 1 year return of 14.7% and a 3 year return of 44.1%. Those figures come in a context where Roche has been viewed primarily as a large, diversified pharma group rather than a pure play obesity name.
The new petrelintide data could influence how the market thinks about Roche’s future mix of growth drivers, especially if late stage studies confirm both efficacy and tolerability. As you weigh this news, the key questions will be how quickly Roche can move into Phase III, what the combination therapy roadmap looks like, and how this obesity program might sit alongside the company’s broader pipeline.
Stay updated on the most important news stories for Roche Holding by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Roche Holding.
SWX:ROG Earnings & Revenue Growth as at Mar 2026
4 things going right for Roche Holding that this headline doesn’t cover.
For Roche, petrelintide looks less like a standalone obesity blockbuster and more like a building block for a broader metabolic franchise. The Phase II data show up to 10.7% mean weight loss at 42 weeks with tolerability that is comparable to placebo, including very low vomiting rates in the maximally effective arm. That profile may matter in a market where injectable GLP‑1 drugs from Novo Nordisk and Eli Lilly already set a high bar on efficacy but often come with gastrointestinal side effects. For you as an investor, the key angle is that Roche now has two obesity assets with positive mid‑stage data, petrelintide and CT‑388. Together, these could open different treatment options across monotherapy and combinations.
This news supports the view that Roche’s pipeline in high value biologics is progressing, adding another potential growth driver alongside existing oncology, immunology and neurology programs.
It also tests the narrative that R&D setbacks are a major overhang, because investors will be watching whether petrelintide can move through late stage trials without repeating the mixed outcomes seen in some other Roche studies.
The obesity focus and co development with Zealand Pharma are not fully reflected in older narratives that lean heavily on diagnostics and oncology, so the potential revenue mix shift toward metabolic disease may be underappreciated.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Roche Holding to help decide what it’s worth to you.
⚠️ The obesity drug market is highly competitive, with established products from Novo Nordisk and Eli Lilly already widely used, so petrelintide will need clear points of differentiation to win share.
⚠️ Roche still faces late stage trial risk, including for petrelintide combinations, and analysts have flagged that R&D setbacks can affect confidence in future earnings.
🎁 Positive Phase II data for both petrelintide and CT‑388 give Roche multiple shots in a large therapy area, which could broaden its set of potential growth drivers.
🎁 The tolerability profile in ZUPREME‑1, with discontinuation rates similar to placebo and mainly mild gastrointestinal effects, may appeal to patients who struggle with side effects on existing obesity drugs.
From here, you may want to watch how quickly Roche locks in Phase III designs for petrelintide, how regulators and clinicians react to the full ZUPREME‑1 dataset once it is presented, and whether ZUPREME‑2 in people with type 2 diabetes shows a similar balance of efficacy and tolerability. Progress on the planned petrelintide plus CT‑388 combination study later in 2026 will also be a key signal of how Roche intends to compete with established obesity players. Any management commentary on where obesity could sit in Roche’s overall revenue mix can help you judge how material this program might become over time.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Roche Holding, head to the community page for Roche Holding to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com